Available for Sale Debt Securities (Tables)

6 Months Ended

Jun. 30, 2022

Investments, Debt and Equity Securities [Abstract]

Summary of Available for Sale Debt Securities

The table below summarizes our available for sale debt securities recorded at fair value as of June 30, 2022 and December 31, 2021 (in thousands):


	Cost		Unrealized Gains		Fair Value		Current Assets		Non-Current Assets		Current Liabilities		Non-Current Liabilities (3)		Total
As of June 30, 2022
Debt securities (1)	$	278,759	$	84,241	$	363,000	$	300,000	$	63,000	$	—	$	—	$	363,000
Forwards (2)	—		28,100		28,100		63,700		—		—		(35,600)		28,100
Funding commitments (2)	(9,400)		1,300		(8,100)		—		—		—		(8,100)		(8,100)
Total available for sale debt securities	$	269,359	$	113,641	$	383,000	$	363,700	$	63,000	$	—	$	(43,700)	$	383,000

As of December 31, 2021
Debt securities (1)	$	204,509	$	49,191	$	253,700	$	66,000	$	187,700	$	—	$	—	$	253,700
Forwards (2)	—		16,700		16,700		—		16,700		—		—		16,700
Total available for sale debt securities	$	204,509	$	65,891	$	270,400	$	66,000	$	204,400	$	—	$	—	$	270,400

(1)Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date.

(2)There are no costs associated with the forwards. The cost associated with the funding commitments represents the fair value on the purchase date.

(3)Reflected within Other liabilities on the condensed consolidated balance sheet.